The RCVS Disciplinary Committee has directed that a veterinary surgeon from Berkshire be removed from the Register, following his administration of a prohibited substance to a racehorse and his subsequent attempts to conceal his actions.
At a six-day hearing that concluded yesterday, James Main, a partner in the O'Gorman, Slater, Main & Partners veterinary practice in Newbury, and former lead veterinary surgeon to racehorse trainer Nicky Henderson, faced four charges of serious professional misconduct concerning his treatment of Moonlit Path, a six-year-old mare owned by The Queen.
Three of the charges related to Mr Main breaching British Horseracing Authority (BHA) rules by injecting Moonlit Path with tranexamic acid (TA) on the day she was due to race; the fourth charge related to his dishonest concealment of this treatment in his practice clinical records. Nicky Henderson had himself faced a BHA Inquiry into this case in 2009 and subsequently been sanctioned.
The Committee heard that on 18 February 2009, Mr Henderson's yard requested a veterinary surgeon attend Moonlit Path to administer an injection of Dycenene the following morning. The injection was requested as the mare was prone to exercise-induced pulmonary haemorrhage. Mr Main attended on the morning of 19 February and injected the horse with intravenous tranexamic acid. Moonlit Path raced at Huntingdon later that day, along with the eventual winner, and favourite, Ravello Bay - another horse trained by Mr Henderson. Moonlit Path finished sixth and a urine sample taken from her after the race tested positive for TA.
Of the four charges, Mr Main admitted injecting Moonlit Path with TA on the day she was due to race when he knew this breached the BHA's rule prohibiting any substance other than the horse's usual feed and water being given on race day. However, Mr Main denied knowing that, if tested, a horse would test positive for TA (thereby imposing a strict liability on the trainer); he denied administering a prohibited substance to a horse with the intention to affect that horse's racing performance; and, he denied dishonestly concealing the TA injection by omitting it from his clinical records and referring to it as a 'pre-race check'.
The Committee heard and carefully considered evidence from Mr Henderson and his employees, from BHA investigating officers and its Director of Equine Science and Welfare, from an expert equine physiologist and from Mr Main himself. In its findings, the Committee stated it was "unimpressed by Mr Henderson's evidence and surprised by his apparent lack of knowledge of the rules of racing".
Whilst the Committee accepted Mr Main believed at the time that Moonlit Path would not test positive for TA, it considered he failed to fully inform himself of the medicinal product he was using; especially so as TA does not possess a Marketing Authorisation as a veterinary medicinal product. In so doing, he did not meet his professional obligation to provide Mr Henderson with the information and advice he needed.
The Committee concluded that TA was a prohibited substance and, whilst accepting that Mr Main's concern had solely been for Moonlit Path's welfare, he had actually breached BHA rules by affecting her performance through administering such a substance.
Finally, the Committee found that Mr Main had deliberately concealed the TA injection to Moonlit Path by describing it in his notes as a 'pre-race check' - a protocol developed over several years between the practice and Mr Henderson. Such inaccurate clinical records were in breach of the RCVS Guide to Professional Conduct and led the Committee to conclude he had acted dishonestly. The Committee also found Mr Main "did not act with candour" by claiming to have administered the TA injection the day before the race. On questioning by the Legal Assessor, however, he admitted that he had known that Moonlit Path was racing the same day that he administered the injection.
Professor Sheila Crispin, chairing the Committee, said: "[We] regard it as wholly unacceptable practice that a veterinary surgeon should be party to serious breaches of rules of another regulatory body in the field of animal welfare ... and which go to the very integrity of racing.
"Whilst the findings relate to a single incident, [we] are satisfied that Mr Main's actions amounted to pre-meditated misconduct ... It is highly relevant that Mr Main held positions of responsibility within the racing industry where he was required to uphold the rules and standards of the profession," she added.
Noting Mr Main's "long and hitherto unblemished career as a highly respected equine veterinary surgeon", the Committee accepted Mr Main's evidence that the reason for the administration of tranexamic acid was solely his concern about the welfare of the horse. Nevertheless, it found his evidence was "evasive, lacking in candour and on some aspects of the case his evidence was untrue".
Professor Crispin concluded: "...proven dishonesty has been held to come at the top end of the spectrum of gravity of disgraceful conduct in a professional respect ... Having considered carefully all the mitigation put forward on Mr Main's behalf, [we] have concluded that Mr Main's behaviour was wholly unacceptable and so serious that removal of his name from the Register is required."
The RCVS Disciplinary Committee has directed that the name of a veterinary surgeon who formerly practised in Norwich should be removed from the Register, having found him unfit to practise veterinary surgery following his Crown Court conviction for fraud.
During the one-day hearing, the Disciplinary Committee heard how Francisco da Cruz had abused his position whilst practising as a veterinary surgeon at Hellesdon Vets, his then workplace in Norwich, by defrauding a insurance companies of around £10,000 with fictitious claims for veterinary treatment on non-existent pets.
Following an investigation by the City of London Police's Insurance Fraud Enforcement Department (IFED), Mr da Cruz was convicted on five counts of fraud by false representation on 21 February 2013 at the Old Bailey in London, and later sentenced to eight months' imprisonment (suspended for two years) and 200 hours of unpaid community work; he was also ordered to pay just over £10,000 in compensation and costs.
Although Mr da Cruz had left the UK for Brazil shortly after his sentencing and was therefore not present at the hearing, the Committee was satisfied that he was deliberately evading the disciplinary proceedings, rather than being genuinely unable to participate in them, and so the hearing proceeded in his absence.
First accepting the copy certificate of conviction against Mr da Cruz as true, the Committee then had no hesitation in concluding that these convictions rendered him unfit to practise as a member of the veterinary profession. It found that the five counts of fraud were deliberate crimes of dishonesty, committed over a significant period of time and for significant financial gain. He had abused his position as a veterinary surgeon and abused the trust which the insurers placed in him as a professional.
Chairing and speaking on behalf of the Committee, Professor Peter Lees, said: "The Committee has no real confidence that there is no significant risk of repeat behaviour from the Respondent. His conduct subsequent to the criminal proceedings gives it no confidence that he has reformed himself to the extent that he will in the foreseeable future be fit to return to practice. So far from satisfactorily completing his criminal sentence, it appears that the Respondent has deliberately gone abroad to avoid doing so."
Bearing in mind that the purpose of any sanction it imposed was not to punish Mr da Cruz, but to maintain public confidence in the profession and uphold proper standards of conduct within it, the Committee concluded that the convictions were too serious to allow any sanction other than removal from the Register.
The full details of the Committee's decisions are available on the RCVS website (www.rcvs.org.uk/disciplinary).
The Cheshire-based specialist referral centre provides advanced surgical procedures and specialist veterinary support to practices in north west England and north and mid-Wales.
Its specialist disciplines include orthopaedics, soft tissue surgery, a specialist diabetes clinic, spinal surgery, anaesthesia and intensive care, cardiology, diagnostic imaging, pain management, neurology (medical and surgical), oncology and internal medicine.
Liz Cousins, Northwest's Hospital Manager said: "Following our recent brand transition from Northwest Surgeons to Northwest Veterinary Specialists we are delighted to receive this accreditation.
"The scheme examines every part of what we do, from customer experience, equipment and facilities right through to clinical governance. In a hospital with more than 85 colleagues, that’s a lot of work to do to meet the high standards.
"Our new brand name reflects the range of specialist services we offer and this accreditation gives confidence to fellow veterinary surgeons and pet owners that we really do offer the very best specialist care for pets.
"We continually strive for excellence across the business, and this is another way of demonstrating just how good the specialists are at Northwest Veterinary Specialists."
Picture shows: Matt Gurney, European Veterinary Specialist in Anaesthesia and Analgesia (centre) with Kathryn Humphreys, Head of Nursing, (right), Jenny Pearson, support Services Manager, (left) with the RCVS Hospital Accreditation.
What is 'quality improvement', you ask? Good question. Sure, it's an improvement in, er, quality. But of what?
'Quality improvement' is a term adopted from the human healthcare sector, variously defined as anything which makes: "healthcare safer, effective, patient-centred, timely, efficient and equitable (NHS)", or "the combined and unceasing efforts of everyone—healthcare professionals, patients and their families, researchers, payers, planners and educators—to make the changes that will lead to better patient outcomes (health), better system performance (care) and better professional development (BMJ)."
The RCVS research project, which is being conducted by RAND EUROPE, will assess current perceptions and adoption of quality improvement in the veterinary profession.
Specifically, it'll look at the drivers, barriers and expectations associated with QI, with the ultimate goal of strengthening the support provided to the profession.
Chris Gush, Executive Director of RCVS Knowledge, said: "We are delighted to be launching this research project with RAND Europe.
"We know that many of our colleagues across the profession have embedded quality improvement into their practice to great benefit, while we are also aware that it can be a challenge to do so all of the time.
"This research will provide an unprecedented body of evidence on the experiences and perceptions of QI, which will be critical to how we work to support the sector in this area going forward."
Integral to the research is a survey which all members of the profession are invited to take part in, here: bit.ly/QIvetsurvey.
The survey will be live for six weeks, closing early April. It takes around ten minutes to complete, with a prize of one £150 Amazon voucher on offer. Responses will be anonymised.
You can read more about Quality Improvement on the RCVS Knowledge website, here: https://knowledge.rcvs.org.uk/quality-improvement/
Danilon is used to relieve the pain caused by musculoskeletal conditions, such as osteoarthritis (OA), bursitis, laminitis, and soft tissue inflammation.
Some oral NSAIDs have been shown to increase the risk of gastric irritation¹ - a particular concern when treating of chronic conditions.
However, Animalcare points to a study² in which horses given Danilon Gold showed a reduced number of ulcers and those that did appear were less severe.
The area of gastric mucosa affected was also five times less.
Animalcare says accurate administration is critical for clinical success.
To support this, Danilon Gold is presented in a coloured granule formulation and is now available in both 3g and 10g sachets.
References
Over 90% of the 156 respondents (predominantly vets, but also managers) believed CT was important in first opinion practice, but nearly half did not have access to a scanner.
25% said they were interested in buying a CT scanner, mainly for the improved diagnostics and desire to keep more cases in-house.
The main reasons for not buying a CT scanner were: space, cost and lack of confidence.
Matt Winter, radiologist and CVMO at VetCT said: “Imaging in first opinion practice is evolving rapidly with innovations in veterinary-specific CT technology, modern machines are more available and affordable than ever.
"We need to build confidence through training and understanding of the technology, and the comprehensive support available to practices.”
While practices with a CT scanner felt they were using it optimally for the most part, specialist radiologist reporting emerged as the most significant factor towards optimising its use.
However, a third of respondents not currently using teleradiology (the remote reporting by specialist radiologists of diagnostic images acquired by a practice), said they did not know enough about it and/or hadn’t considered it.
Matt said: “Expert teleradiology to support with image interpretation is enabling more practices than ever to offer advanced imaging and provide state-of-the-art diagnostics for patients, meeting growing client expectations, elevating patient care and improving outcomes."
VetCT’s webinars on CT optimisation are available on Youtube: https://www.youtube.com/c/Vetctspecialists
Zoetis says Lokivetmab targets and neutralizes canine interleukin-31 (IL-31), a cytokine associated with atopic dermatitis which sends the itch signal to the brain.
The company has submitted an application for marketing authorisation of the product, which is conditionally licensed in the US and Canada under the name Canine Atopic Dermatitis Immunotherapeutic, in the European Union.
The new data was presented at the 8th World Congress of Veterinary Dermatology (WCVD).
Supporting the efficacy of Lokivetmab in canine AD, Zoetis presented the results of a randomized, double-blind, placebo-controlled dose determination trial to evaluate efficacy of three doses of lokivetmab (0.125, 0.5 or 2.0 mg/kg) in providing relief from the clinical signs of pruritus (itching) and other clinical signs associated with atopic dermatitis in dogs.
Veterinary investigators at 15 clinics enrolled 245 client-owned, live-at-home dogs with chronic atopic dermatitis. Lokivetmab or a placebo was administered by subcutaneous injection on day 0, and efficacy was evaluated periodically over 56 days. Dog owners assessed their dog’s pruritus using a visual analog scale (VAS), and investigators assessed the associated skin lesions using Canine Atopic Dermatitis Extent and Severity Index-03 (CADESI-03) scores.
Lokivetmab, injected once subcutaneously, provided dose-dependent improvement in owner-assessed pruritus and clinician-assessed CADESI-03 scores for four to six weeks in dogs with atopic dermatitis.
Zoetis also presented results of a randomized, double-blind, placebo-controlled trial to assess the safety of lokivetmab at the nominal dose tested of 1 mg/kg (range, 1-3.3 mg/kg) in the treatment of canine atopic dermatitis. Veterinary surgeons evaluated 245 client-owned, live-at-home dogs with chronic, naturally-occurring atopic dermatitis. These dogs were randomized at a 2:1 ratio to receive two monthly injections of lokivetmab (162 dogs) or placebo on days 0 and 28.
No immediate hypersensitivity reactions were observed and there were no clinically important differences in clinical pathology results. No apparent adverse drug interactions were reported. Dogs studied were taking a wide variety of medications, which is important because multimodal therapy is commonly prescribed for dogs with atopic dermatitis. Adverse events were reported at a similar frequency between the groups.
The survey is open to all veterinary surgeon members and participants will be entered into a free prize draw to win £500 of BEVA CPD vouchers.
As we all know, antibiotic resistance is increasing throughout human and veterinary medicine, and there are few new antibiotics being produced. As BEVA says, it’s therefore imperative for vets to protect the usage of antimicrobials to maintain their effectiveness for the future.
To that end, the purpose of the survey is to help fill in gaps in knowledge about how antimicrobials are being used and also the current landscape of resistant infections encountered in equine practice.
The survey has been designed by Amie Wilson and Dr Gina Pinchbeck at the University of Liverpool and Tim Mair the incoming President of BEVA.
Tim said: "This survey will assess any changes in prescribing of antimicrobials in equine practice since the last survey in 2009. In addition, we will collect data on the current frequency and types of antimicrobial resistant infections seen by clinicians in all areas of equine practice and what infection control and audit practices are currently using to combat this."
The survey results should lead to a greater understanding of the role of antimicrobial treatment in the overall epidemiology of antimicrobial resistance in horses and will help protect antibiotics for the future of equine and human health.
To take part in the survey, visit: https://liverpool.onlinesurveys.ac.uk/beva-questionnaire-2019-final
The results will be announced to coincide with European Antibiotic Awareness Day on 18 November 2019.
If you have any questions about the survey you can contact the researchers direct: Amie Wilson, University of Liverpool A.wilson3@liv.ac.uk; Dr Gina Pinchbeck, University of Liverpool ginap@liv.ac.uk; Tim Mair, British Equine Veterinary Association tim.mair@btinternet.com
CVS says that in the USA, the veterinary profession is the fifth highest profession for non-fatal injuries, with equine veterinarians sustaining an average of eight serious injuries during their career.
‘The context, consequence and prevention of veterinary workplace injuries: a qualitative and quantitative study in the UK’ will be undertaken at the University of Liverpool in collaboration with CVS colleagues as part of its Clinical Research Awards.
The study will run for three years, supported by £74,400 of CVS funding.
The research will investigate what veterinary injuries are, what context they occur in and what their consequences are.
It will look to highlight areas of the profession where injury prevention training and strategies can be developed and adopted to improve the safety of working in veterinary practice.
For the first phase, University of Liverpool researchers have rolled out the largest ever survey to explore veterinary workplace injuries with over 5,000 CVS staff UK-wide.
The survey investigates how veterinary professionals define injuries, their specific causal mechanisms, and why individuals do or do not report injuries or seek medical treatment.
The survey will be followed by an independent audit of CVS’ accident reporting system.
The results of these two activities will lead to the development of a suite of industry leading ‘open access’ educational tools aimed at promoting injury awareness and prevention to help drive behaviour change and support injury avoidance.\
The research project is being led by Dr. John Tulloch, a Research Fellow and European Specialist in Veterinary Public Health, at the University of Liverpool.
Collaborators include CVS Head of Health and Safety Rebecca Jackson and Director of Learning, Education and Development Dr Martin Whiting.
John said: “Injuries that occur within veterinary practice can tragically at times be life-changing and are often avoidable.
"Currently we do not know some critical details that would help to improve safety within the veterinary workplace.
"If we can better understand these details, we will be able to develop and strengthen prevention measures through policy, education, and training.
"We anticipate that this project will result in safer workplaces within the wider veterinary community and, indirectly, in improved animal treatment through a fitter, healthier and safer profession.”
Running throughout October, it is Ceva's third TV campaign this year to raise awareness of the benefits of Feliway and Adaptil amongst pet owners.
The campaign starts with a Feliway Classic advertisement running from 3rd October until 16th October, followed by an Adaptil advertisement until 30th October, timed for the run up to the firework season.
The new TV advertising campaign will target 18.5 million pet owners and it will air on all the C4 channels, including Channel 4, E4, More4, Film4, Drama, Good Food, Really, W and Home, with two spots during the popular Channel 4 TV show Great British Bake Off, which has 6.7 million viewers.
The TV advertising campaign will be supported by a Sky Adsmart and social media campaign for ADAPTIL.
Claire Russell, product manager for Feliway and Adaptil at Ceva Animal Health, said: "Our autumn Feliway and Adaptil TV advertising campaign is our biggest, most extensive campaign to date. It demonstrates our commitment to raising awareness of how anxiety in pets can affect the relationship with their owners and how Feliway and Adaptil can help."
For further information, visit www.feliway.com or www.adaptil.com.
The NOAH Code of Practice Committee, chaired by Mr Guy Tritton, has found Dechra Veterinary Products in breach of three items of the NOAH Code, following a complaint.
The complaint related to an advertisement and detailer promoting Felimazole with the wording "Are you taking a heavy-handed approach to hyperthyroidism?" and "with Felimazole, you don't have to!"
The Committee took the view that by implication this referred to Vidalta because Vidalta is the only other licensed oral treatment on the market for hyperthyroidism.
As a result, the Committee found both promotions in breach of Clause 4.3 because of the implication that Vidalta is less safe than Felimazole.
The Committee did not consider the promotions disparaged the manufacturer as there is no evidence to show it is unsafe.
The Committee also found that the table in the detailer (page 4) suggesting that one dosage of 5 mg per day of Felimazole has the same efficacy as two doses of 2.5 mg, (which is contrary to the dosing statement within the SPC: "If, for reasons of compliance, once daily dosing with a 5 mg tablet is preferable, then this is acceptable although reduced efficacy can be expected compared to a twice daily regime.") was misleading, contrary to Clause 4.3 of the Code.
Full details of the Committee's rulings are on the NOAH website at www.noah.co.uk/code. The full report of this particular case will be available shortly.
The allied professionals that the BVA says should be led by veterinary surgeons include: Registered Veterinary Nurses (RVNs), Official Auxiliaries/ Meat Hygiene Inspectors, embryo transfer technicians, equine dental technicians, foot trimmers, farriers, hydrotherapists, animal behaviourists and veterinary physiotherapists.
To clarify where the responsibility for a patient sits and how it is shared between veterinary surgeons and allied professionals, the new policy statement also calls for:
The regulation of allied professionals to include mandatory veterinary diagnosis and oversight and appropriate access to veterinary records as pre-requisites before treatment;
Clarity on the delegation of duties for RVNs under Schedule 3 of the Veterinary Surgeons Act and protection of the ‘veterinary nurse’ title in legislation;
Consultation with the veterinary profession on any regulatory changes that may arise as a result of technological or other innovation.
British Veterinary Association President Simon Doherty (pictured right) said: "Against an evolving landscape, it’s essential that the veterinary profession keeps pace with change and addresses the challenges and opportunities it presents.
"Vets across sectors have always worked closely with allied professionals. The hub and spoke model acknowledges and clarifies this working relationship with clear lines of accountability and responsibility for the animals under our care. It also emphasises that vets’ right to diagnose, prescribe, and undertake surgical procedures and medical treatments must not be undermined.
"An effective and efficient vet-led team can help deliver better animal health and welfare, improved client care, and more effective use of skills within the veterinary professions. Given the ongoing workforce shortages, a strengthened veterinary workforce also has the potential to ease recruitment and retention concerns for both vets and RVNs and offer improved wellbeing.
"BVA will continue working with professional bodies and organisations to formalise the hub and spoke model, promote the value of regulation, and drive up professional standards."
Divided into four modules, the course explores vaccines and the immune system; current and emerging strains of Leptospirosis; a practical insight into infectious disease and vaccination and the importance of getting early socialisation right.
Professor Sarah Gilbert from the Jenner Institute in Oxford presents the first CPD module. She is followed by Dr Paul Burr from Biobest Laboratories, Alan Radford from the University of Liverpool and Jon Bowen of the RVC.
John Toole, Zoetis Product Manager said: "We were extremely privileged to be able to work with such an eminent group of key opinion leaders for this CPD course. We hope participants find the interview video style of this course dynamic and insightful. Users can also find an additional module on our dog vaccine Versican Plus and how it helps meet today’s infectious disease challenges as discussed by our industry experts."
To take part in this new CPD, vets simply need to register at www.vetsupportplus.co.uk where they will be able to access all the free Zoetis learning content and receive a certificate once the CPD course is completed.
The study1 was led by the RVC’s VetCompass programme and included 22,333 dogs whose health was followed for a year, during which 1,580 were recorded by the vet as overweight; roughly 1 in 14.
The authors point out that this figure is probably just the tip of the iceberg, because not every overweight pet will receive veterinary attention.
The study also found that certain breeds were especially prone to weight gain, including Pugs, Beagles, Golden Retrievers and English Springer Spaniels.
As well as showing that specific breeds were at differing risk, the study also highlighted that being neutered and middle-aged were additionally associated with increasing chances of dogs being overweight.
The main findings were:
Owners are encouraged to discuss their dog’s weight and lifestyle on every visit to their veterinary practice. This is of particular importance in the high-risk dogs identified in this study such as Pugs, Beagles, neutered and middle-aged dogs.
Camilla Pegram, VetCompass Epidemiologist at the RVC, and author of the paper, said: "This study has used the power of “big data” to robustly address the risk factors for obesity in dogs. Pugs, Beagles and Golden Retrievers were at greatest risk of obesity compared with crossbreeds.
"As well as genetics, management style could in part drive these breed predispositions. Whilst veterinary professionals and owners should focus efforts on obesity prevention strategies in all dogs, those identified at high-risk, such as Pugs, Beagles and Golden Retrievers, may need a more targeted approach."
Dr Eleanor Raffan, Associate Lecturer in Systems Physiology, at the University of Cambridge, and co-author of the paper, said:
“Where breed increases risk of a problem, it means genes are likely to be at least in part to blame and our previous work suggests that genetics drives a high appetite in some breeds. The bad news is that owners of food-obsessed dogs have to work much harder to keep their dogs at a healthy weight – the good news is that it can be done.”
Reference
The reports summarise the results of two surveys that were conducted between July and August last year.
Of the 28,718 veterinary surgeons who were sent the survey, 22% fully completed and submitted the questionnaire.
Some of the main findings included:
Around 40% of veterinary surgeons and over 40% of veterinary nurses said they had experienced concerns for their personal safety aside from catching Covid.
These safety concerns mostly related to client interactions at the practice either during the day or out-of-hours.
Many respondents experienced conflict between their personal wellbeing and professional role, and found it difficult to juggle their work and caring responsibilities.
Many respondents also said their mental health was adversely affected by the experience of working during the pandemic.
A large majority of respondents said they had personally seen an increase in caseload due to new animal ownership.
Lizzie Lockett, RCVS CEO, said: “While many of the results of the survey may not be especially surprising and confirm what we have already been told anecdotally, it is very important that we have this hard data to hand on the overall impact of the pandemic on individual members of the professions.
“These two reports complement the six surveys that we have conducted with veterinary practices on the economic impact of the pandemic to give us as clear and holistic a picture as possible about the challenges that the professions and the veterinary sector as a whole have faced since March 2020.
"This not only provides a useful historical snapshot, but builds an evidence base to inform future temporary changes should the pandemic continue into more waves, or should future such crises arise.
“The results of the two individual surveys make it clear it has been a tough time for the professions.
"A good proportion of respondents also acknowledged that positive developments have come from the past two years, including the way the profession has demonstrated remarkable resilience, flexibility and adaptability, as well as forging a stronger team spirit under such difficult circumstances.
“However, a large number of both vets and vet nurses who responded said that the experiences since March 2020 have left them feeling more pessimistic about veterinary work and their place within it.
"I would like to reassure members of the veterinary team that the RCVS is aware and understands.
"We tried throughout the pandemic to support the professions with relevant temporary guidance changes, and we are now working with a range of stakeholders on critical issues such as the workforce crisis, which has been in part caused by Covid.
"We are also developing tools, training and resources to support the professions, via our programmes such as RCVS Leadership and Mind Matters.”
The full coronavirus impact survey reports can be found at www.rcvs.org.uk/publications.
Eurovet Animal Health has launched Marbiflox 10%, a new marbofloxacin preparation for the treatment of respiratory infections in cattle and pigs.
Eurovet says the product can be used flexibly to provide a single dose treatment, with a concentration-dependent effect and a relatively short withdrawal period. Marbiflox can be administered intravenously, subcutaneously or intramuscularly in cattle or intramuscularly in pigs.
The main indications, with reference to good prescribing practice, are for the treatment of respiratory infections caused by sensitive strains of Pasteurella multocida, Mannheimia haemolytica, and Histophilus somni and acute forms of mastitis induced by marbofloxacin-sensitive Escherichia coli strains, during lactation. In pigs the main indication is in the treatment of MMA (metritis mastitis agalactia syndrome).
Further information about Marbiflox and the complete Eurovet range of products is available from Eurovet Animal Health. www.eurovet-ah.co.uk/.
Armed with the new microscope, New Forest Equine Vets (NFEV) has started offering a mobile equine veterinary service, including expert worming advice.
The microscope captures images with a resolution of 1 micron, with a live magnification of x200 and x400 or more, which means that the practice can carry out an accurate egg count in the yard, rather than sending faecal samples off to the lab.
This, they say, allows for a more a more accurate result, because posting faeces can lead to the sample desiccating and the eggs hatching, leading to false negative results. It also allows the veterinary surgeon to give immediate advice and treatment.
Dr. Beth Robinson BVSc Cert AVP(EP) MRCVS, co-owner of NFEV, says "One of the main aims of performing worm egg counts is to identify horses shedding low numbers of eggs so that we can maintain a low number of parasites on the pasture that have not been exposed to wormers and therefore have not been placed under selection pressure for resistance. In horses shedding high numbers of eggs, worm egg count reduction tests are a useful way of assessing whether treatment has been effective."
Andrew Monk, co-founder of ioLight, said: "The product is incredibly simple to use. By using a tablet both the owner and vet can view the image and discuss treatment. We hope that more horse owners in the New Forest will use the services from NFEV to protect their animals, and that it will encourage other equine practices to purchase a microscope so they can also offer a similar high quality service. We have made a video with NFEV to demonstrate their service and encourage other equine vets to use the ioLight microscope in their own mobile clinics."
Beth added: "We are delighted to be working with ioLight and horse owners to keep their animals healthy and improve equine welfare."
Research commissioned by Bayer Animal Health has revealed that dogs really do look like their owners.
The research, which is being used to promote Drontal Bone, the company's new bone-shaped wormer, was conducted amongst 3,000 British dog-lovers. It found that the overwhelming majority of owners share at least one common physical attribute with their pet, whilst one in ten owners could be described as the spitting image of their dog, sharing six or more physical attributes:
As part of the campaign, Bayer has launched the Give Your Dog a Bone competition, a nationwide search to find the UK's "Top Dog". The competition is split into four video and photographic categories, with one open exclusively to dogs that have formed a special bond with their owner. Top dogs can enter via the competition website - www.giveyourdogabone.co.uk - where owners can upload photos, videos, and explain in under 100 words why they think their pet should win a Drontal 'Bonies' award.
Give Your Dog a Bone Judge Emma Milne MRCVS, said: "When dogs seem to have the same characteristics as their owners, it could be because people subconsciously choose a pet that resembles themselves. It is often found that more energetic breeds, such as s Red Setter have an owner who is sporty and most happy when taking their pet on long country walks, while a glamorous owner who enjoys grooming themselves might choose a dog which also requires lots preening, such as a Maltese Terrier. The Give Your Dog a Bone awards give us the chance to recognise the unique traits and talents that make dogs such an important part of our lives. With four very different categories, this competition will be wide open to dogs of all shapes, sizes and personalities!"
Norbrook has verified that the pH of certain batches has increased over time and is out of specification.
This issue impacts the following batches:
A spokesperson said: "There has been no increased risk to animal safety identified but we take quality extremely seriously so we initiated a voluntary recall. We have informed all of the competent authorities and we are working with our distributor to advise immediate quarantine of any remaining inventory."
If you have any questions concerning the recall, contact Ms. Anita Vanderlaan Tel: +44 (0)28 3026 4435, Email: anita.vanderlaan@norbrook.co.uk
Zoetis has launched Suvaxyn Parvo/E, a combined vaccine which it says provides the earliest protection of gilts against parvovirus and erysipelas.
Parvovirus and erysipelas infections occur primarily in gilts and sows, negatively impacting their reproductive success and the health of their litters - inevitably reducing profitability.
Nigel Lodge, National Veterinary Manager for Zoetis, said: "The combined vaccine will help ensure the health of gilts and sows is not affected by these two infections which are widespread in the pig herd.
"Suvaxyn® Parvo/E gives the earliest protection so that the ability to vaccinate gilts at five months of age will help ensure a good start to their reproductive life. Up to half of all pigs may be carriers of erysipelas and importantly the vaccine has licensed efficacy against both Erysipelothrix serotypes 1 and 2.
"This brings another vaccine to our portfolio, making it one of the largest in the pig sector and confirming the ongoing commitment of Zoetis to the health and welfare of pigs."
Suvaxyn® Parvo/E is an inactivated combination vaccine approved for immunising gilts and sows to prevent reproductive disorders caused by porcine parvovirus and reduce clinical signs caused by Erysipelothrix rhusiopathiae.
Primary vaccination is recommended from five months of age, with two injections given three to four weeks apart, ensuring the second dose occurs at least four weeks before mating. Revaccination should take place three to four weeks before each subsequent mating.
The vaccine comes in 10-dose and 2 X 25-dose packs. For more information, contact your Zoetis Pig Key Account Manager.
The award, funded by the Economic and Social Research Council (ESRC) working in partnership with the Department of Health and the Arts and Humanities Research Council (AHRC), is part of the cross-council 'Tackling antimicrobial resistance: behaviour within and beyond the healthcare setting’ call, part of the antimicrobial resistance cross-council initiative supported by the seven research councils in partnership with other UK funders including the Medical Research Council (MRC).
The research team will be led by social scientists at the University of Exeter and includes two veterinary surgeons from the University of Bristol’s School of Veterinary Sciences, together with colleagues at the Innogen Institute of the University of Edinburgh, the British Veterinary Association and leading farm animal veterinary surgeons across the UK.
The researchers say that better, smarter, more rapid and more accessible diagnoses - driving shifts in behaviour associated with diagnostic decision making - represent a critical step to delivering more effective uses of antibiotics in animal health. But improvements in diagnostic development and their relationship to prescription and treatment requires social, governance and technical innovations.
Professor Henry Buller, project lead from the University of Exeter’s School of Geography, said: "This is an exciting opportunity to provide a current assessment of diagnostic and treatment decision practices in the livestock sectors of the UK. Novel and innovative diagnostic tools are currently in development, and our research will generate better understanding of their development as well as the marketing and regulation of these new technologies."
Dr Kristen Reyher, Senior Lecturer in Farm Animal Science, who is the lead on the project at the University of Bristol’s School of Veterinary Sciences, added: "Our research team – the AMR Force – has a track record of working closely with farmers, veterinarians, retailers and government bodies to encourage responsible use of antibiotics. We are excited to have this amazing opportunity to collaboratively generate, evaluate and analyse behaviours and strategies around animal disease diagnosis and to show how innovation in the development of diagnostic tools along with diagnostic regulation and governance can lead to more sensible use of antibiotics across farming systems.
"Working with our partners, we will identify pathways and possibilities for improved diagnostic practice and will trial new diagnostic tools on a series of farms. We are very excited to take our ideas beyond the UK as well, and will conduct pilot and capacity-building research in Tanzania and also partner with a project working in Bangladesh that is co-funded by ESRC and the Centre for Environment Fisheries and Aquaculture Science."
Professor Buller added: "Employment of new diagnostics doesn’t occur in a vacuum. Our team will evaluate the implications these innovations will have for the organisation, cost-effectiveness and efficiency of veterinary practice, as well as for veterinary training. We will identify the changes in behaviour, practice and knowledge necessary to accompany the more widespread adoption of practices that are deemed effective and will assess the regulatory and governance support necessary to encourage use of beneficial practices."
The interdisciplinary team will work alongside diagnostic tool developers and regulators, veterinary practices and professional bodies, farmers and treatment decision makers, veterinary laboratories, the food industry and government regulatory authorities to develop durable and innovative strategies for facilitating and advancing smarter approaches to the use of antibiotics in agriculture.
The work will cover the major livestock species, and will involve seeking opinions from veterinary surgeons across the country, through collaboration with the BVA.
David Barrett, Professor of Bovine Medicine, Production and Reproduction at the University of Bristol’s School of Veterinary Sciences, said: "This is a fantastic opportunity to assess the adaptability and responsiveness of the different animal production sectors - poultry, pigs and cattle - along with a variety of veterinary structures to the trialled innovations in diagnosis and diagnostics, and will determine the likely benefits of these innovations for prescription practice, for animal health and for sustainable livestock production."
Photo: University of Bristol
The Investigating Committee and the Disciplinary Committee are responsible for conducting desk-top investigations and disciplinary hearings in response to complaints, disclosures and notifications that may amount to serious professional misconduct by Registered Farriers.
As the Royal College of Veterinary Surgeons did in 2015, the FRC is splitting off its disciplinary functions from that of its Council, meaning it now needs to recruit new members to perform the role.
More information is available in VetSurgeon Jobs, here.
"The majority of veterinary medicines used in the UK (and ingredients and components to make them) are either produced in or enter via the EU. The government is working with animal health companies who have been carrying out extensive contingency planning for all EU Exit scenarios, including no deal. These plans cover all aspects of their supply chains, from regulatory compliance and stocking levels to logistics and customs. They also include, as appropriate, increasing stocks of products in the UK, changing supply routes, transferring marketing authorisations and other regulatory processes.
"To reduce any risk to medicines availability in the UK, detailed planning is ongoing to ensure that supply chain measures are appropriate to address the sector’s complex needs and priorities.
"Much work has been done by companies with the objective of ensuring fair and appropriate distribution of this inventory to avoid disruption.
"Supply is expected to cope with a normal ordering pattern with adequate forward planning and communication with suppliers.
"With this planning in place, we are confident that we have made every effort to ensure continuity of supply of veterinary medicines in the UK."
Well that makes a nice change from the incessantly and determinedly gloomy picture painted elsewhere.
Intervet/Schering-Plough Animal Health has launched Posatex (1% Orbifloxacin, 0.1% Mometasone Furoate Monohydrate and 0.1% Posaconazole, Otic Suspension), a new once-a-day treatment for otitis externa in dogs.
Posatex combines an antibacterial, an anti-inflammatory and an antifungal medication in one, seven-day treatment which the company describes as the 'next generation' treatment for severe otitis externa in dogs, designed to make compliance easier and bring fast relief to dogs suffering from this painful condition.
Allan Weingarten, Director, Pharmaceutical Research, and Posatex R&D Project Leader, said: "As every dog owner knows, this is a 'nightmare' disease. As experts in otic products, we feel a special responsibility to keep improving medications and continuing to make the course of treatment more effective, quicker and easier for both dogs and their caregivers. The novel triazole antifungal posaconazole, new to animal health, is the latest example of innovation in this product area."
Posatex Otic Suspension, available in 7.5, 15 and 30g plastic bottles, is indicated for the treatment of otitis externa associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (coagulase positive staphylococci, Pseudomonas aeruginosa and Enterococcus faecalis).
According to the company, posaconazole, the newest element in the three-in-one combination, has been shown to be particularly effective against Malassezia pachydermatis and more potent than other veterinary antifungals. Mometasone furoate monohydrate is a potent and safe anti-inflammatory and Orbifloxacin is a broad-spectrum antibiotic with proven efficacy against bacteria.
Consistent with previous surveys, lameness was shown to be more likely to be caused by conditions such as osteoarthritis in the limb rather than problems in the foot.
Blue Cross carries out NEHS in May each year in partnership with the British Equine Veterinary Association (BEVA). It is sponsored by Dodson & Horrell and Zoetis and supported by the UK’s leading equestrian organisations and charities.
This year saw a 14% increase in participation compared to 2015, with survey records returned for almost 16,751 horses, ponies, donkeys and mules and 5635 people taking part. Most horses were kept in livery or a private yard and used for leisure and hacking.
Lameness has been consistently seen as the most common syndrome affecting horses in the NEHS results year on year. In the latest survey a total of 32.9% (24.4% in 2015) of horses and ponies with health problems were recorded as lame. Overall, as in previous years, lameness in the limb was more common than lameness caused by problems in the foot.
A breakdown of the types of lameness revealed that 47.4% were recorded as suffering from proximal limb lameness, 31.9% from causes of foot lameness other than laminitis and 20.7% from laminitis. Degenerative joint disease (including foot and proximal limb) was the most frequently reported single cause of lameness (41.2% of all lameness) and the most frequently reported joint affected by DJD was the hock (15.3% of all lameness).
Reports of foot lameness (excluding laminitis) more than doubled this year at 10.5% (4.5% in 2015) of all syndromes reported with pus in the foot being the most frequently recorded problem. This could possibly be attributed to the persistent wet weather during and prior to the survey, which can increase susceptibility to the condition.
Josh Slater from the Royal Veterinary College, who is a member of BEVA’s Health & Medicines Committee and analysed the NEHS data, said: "The data gleaned from the survey remains consistent year on year, confirming the reliability of our findings for benchmarking, referencing and research. This year’s increase in overall lameness may be in part attributed to the higher incidence of pus in the foot but may also be because owners are becoming more aware of lameness issues. Ongoing research on lameness has generated significant media coverage over the past year, helping to raise understanding of the importance of accurate diagnosis and treatment both from welfare and performance perspectives."
The six most notable disease syndromes identified in the 2016 National Equine Health Survey are:
Gemma Taylor, Education Officer at Blue Cross said: "The significant increase in participation again this year shows that owners and keepers of horses are really getting behind the survey and recognising its importance in safeguarding the future health and of the UK’s horses. Over the past year NEHS data has been referred to in leading equestrian and veterinary media, showing its credibility as a valuable benchmarking reference."
The 2016 NEHS survey results are now available. To download a copy visit http://www.bluecross.org.uk/nehs2016results and to register for next year’s survey please visit www.bluecross.org.uk/nehs